Clarity Pharmaceuticals Ltd. (($AU:CU6)) announced an update on their ongoing clinical study. Clarity Pharmaceuticals Ltd. is conducting a Phase 3 ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved P ...

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...